Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Keywords

Medicine, Expert opinion, Minimal residual disease, Genetic testing, Disease

References

• New designs for phase 2 clinical trials.Victoriano Sierra Ludwing — 2003
• Interleukin-4 Stimulates Proliferation and Growth of T-Cell Acute Lymphoblastic Leukemia Cells by Activating mTOR SignalingNorma P. Nickerson, Megan Schultz — 2008
• Anthracycline dose intensification in acute myeloid leukemia.E.G. Sadjere, GO Ariavie, PO Ebunilo — 2009
• Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.Mary S. Koske, Regina Bendix — 2010
• Prognosis and Therapy When Acute Promyelocytic Leukemia and Other “Good Risk” Acute Myeloid Leukemias Occur as a Therapy-Related Myeloid Neoplasm修 斎藤 — 2011
• Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation.G. Bompeix, André Ravisé, G. Raynal — 2012
• Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T‐cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factorsLuis Arturo Hernández — 2013
• Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remissionM. Ryan Corces, Wan‐Jen Hong, Irving L. Weissman — 2014
• MRD in AML: it is time to change the definition of remission.Marisa Inda Putri — 2014
• A New Statistical Method for Dose-Finding Based on Efficacy and Toxicity in Early Phase Clinical TrialsPeter F. Thall, Elihu H. Estey, Hsi‐Guang Sung — 2004
• Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with >30% Bone Marrow Blasts Treated with Azacitidine By Cytogenetic Risk Status: Results of the AZA-AML-001 StudyHartmut Döhner, John F. Seymour, Aleksandra Butrym — 2014
• Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospectsN-C Gorin, Sebastian Giebel, Myriam Labopin — 2015
• Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaThe Cancer Genome Atlas Research Network — 2013
• Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid MalignanciesMarcelo C. Pasquini, Mei-Jie Zhang, Bruno C. Medeiros — 2015
• Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA TrialCharles Craddock, Nadira Jilani, Shamyla Siddique — 2016
• A comparison of Daunorubicin/Ara-C (DA) versus Daunorubicin/Clofarabine (DClo) and two versus three courses of total treatment for older patients with AML and high risk MDS: results of the UK NCRI AML16 Trial [Abstract]Alan K. Burnett, Nigel H. Russell, Jonathan Kell — 2012
• Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group–an observational analysis by the Acute Leukemia Working Party of the EBMTJakob Passweg, Myriam Labopin, Jan J. Cornelissen — 2015
• Immunotherapy in acute myeloid leukemiaDolores Grosso, Rosemary Hess, Mark A. Weiss — 2015
• FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia.Michael R. Grunwald, Mark J. Levis — 2015
• Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:Hagop M. Kantarjian, Susan O’Brien, Jörge E. Cortes — 2006

Cited by

• Outcomes of patients diagnosed with acute myeloid leukemia after solid organ transplantationS. G. Bodrov, А. Д. Данилов, A.I. Rusakov — 2017
• Treatment of acute myeloid leukemia in the next decade - Towards real-time functional testing and personalized medicine.B Anzaldo Campos, Ricardo Adalberto — 2017
• Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemiaYing-Shing Shiao, Ding-Tsair Su, Jui-Liang Yang — 2018
• Can we forecast induction failure in acute myeloid leukemia?正吾 武川 — 2018
• Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformationKenneth Christiansen, Peter Bellinger — 2018
• Correlation of TET2 SNP rs2454206 with improved survival in children with acute myeloid leukemia featuring intermediate‐risk cytogeneticsTatsuya Mori — 2018
• Social preferences for health states associated with acute myeloid leukemia for patients undergoing treatment in the United KingdomEd Loxterkamp — 2018
• Universal monitoring of minimal residual disease in acute myeloid leukemia.Eduardo Canul, Eddie Aparicio — 2018
• Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission.Santiago Carbó Valverde — 2018
• Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia RelapseJosé Ramón Rodríguez Carbajo — 2018
• FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemiaJonas Westhus, Richard Noppeney, Ulrich Dührsen — 2018
• Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remissionXavier Baró i Queralt — 2018
• Myeloid malignancies with somatic GATA2 mutations can be associated with an immunodeficiency phenotypeJosé María Suñé Arbussà — 2019
• Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinicallyUlrich Soltész, Anne Schädle — 2019
• Non‐acute promyelocytic leukemia variant, acute myeloid leukemia with translocation (11;17)Isabelle Cabrol — 2019
• Molecular characterization of acute myeloid leukemia patients who relapse more than 3 years after diagnosis: an exome sequencing study of 31 patientsJosé Andrés Vázquez — 2019
• Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and realityVeloz Ávila, Norma Ilse — 2020
• Akute myeloische LeukämieChristoph Röllig, Christian Thiede, Gerhard Ehninger — 2017
• Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.D. Hoelzer, Renato Bassan, Hervé Dombret — 2016
• Deciphering the oncogenic network of PRC-2 loss guided leukemogenesisDavid J. Schneider, Jan‐Henning Klusmann, Dirk Heckl — 2016

Related papers

• Comparison of minimal residual disease (MRD) estimated by flow cytometry and by real-time quantitative PCR of Wilms tumor gene 1 (WT1) transcript expression in children with acute lymphoblastic leukemia.Jiann-Shiuh Chen, Chih‐Cheng Hsiao, Jiunn‐Ming Sheen — 2007
• A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groupsCarlos Alberto Scrideli, Juliana Godoy Assumpção, MA Ganazza — 2009
• Next-Generation Sequencing for Minimal Residual Disease Surveillance in Acute Lymphoblastic Leukemia: An Update.Cynthia Reyes-Barron, Richard Burack, Paul G. Rothberg — 2017
• Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemiaGeoffrey Neale, Elaine Coustan‐Smith, Patricia Stow — 2004
• EVALUATION OF RELATIONSHIP BETWEEN MINIMAL RESIDUAL DISEASE (MRD) AND RELAPSE IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) USING QUANTITATIVE FLUORESCENT PCRRasoul Salehi, Salehi Mansour, Alireza Moafi — 2005
• Detection of minimal residual disease in pediatric acute lymphoblastic leukemiaGiuseppe Gaipa, Giuseppe Basso, Andrea Biondi — 2013
• Advances in the detection of minimal residual diseaseJerry Radich, Blythe Thomson — 1997